GNTI-148, an allogeneic engineered Treg product for the treatment of type 1 diabetes
GNTI-148
Allogeneic EngTreg
- Allogeneic version of GNTI-122
- Recently diagnosed T1D patients positive for DRB1*04:01 allele
- Development candidate in 2026
GNTI-148 is an allogeneic engineered Treg (EngTregs™) product being developed for newly diagnosed type 1 diabetes patients to protect beta cells from destruction by the immune system. Leveraging the properties of EngTregs and Immune Evasive Engineering, GNTI-148 is designed to durably support repair and improve function of inflamed and damaged beta cells in an allogeneic setting. Its allogeneic design facilitates scalable, cost-effective manufacturing and immediate availability—bringing a transformative approach to halting disease progression in newly diagnosed patients.